Article Details
Retrieved on: 2021-04-01 12:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Theravance Biopharma (NASDAQ:TBPH) had its target price cut by investment analysts at SVB Leerink from $41.00 to $40.00 in a report issued on ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here